Jekaterina Shubina

Ms. Jekaterina Shubina

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MKMaria Vladimirovna Kuznetsova
Maria Vladimirovna Kuznetsova
NSNelly S. Sogoyan
Nelly S. Sogoyan
ADAndrew J. Donnikov
Andrew J. Donnikov
DTDmitry Y. Trofimov
Dmitry Y. Trofimov
LALeila V. Adamyan
Leila V. Adamyan
GSGennady T. Sukhikh
Gennady T. Sukhikh
In order to determine genetic loci associated with decreasing risk of uterine leiomyomata (UL), a genome-wide association study (GWAS) was performed. We analyzed a group of patients with a family history of UL and a control group consisting of patients without uterine fibroids and a family predisposition to this pathology. Six significant single nucleotide polymorphisms were selected for PCR-genotyping of a large data set of patients with UL. All investigated loci (rs3020434, rs11742635, rs124577644, rs12637801, rs2861221, and rs17677069) demonstrated the lower frequency of minor alleles within a group of women with UL, especially in a subgroup consisting of patients with UL and a familial history of leiomyomata. We also found that the minor allele frequencies of these SNPs in our control group were higher than those across the Caucasian population in all. Based on the obtained data, an evaluation of the common risk of UL was performed. Further work will pave the way to create a specific SNP-panel and allow us to estimate a genotype-based leiomyoma incidence risk. Subsequent studies of genetic variability in a group of patients with a familial predisposition to UL will allow us to make the prediction of the development and course of the disease more individualized, as well as to give our patients personalized recommendations about individual reproductive strategies.

28 August 2020 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
JSJekaterina Shubina
Jekaterina Shubina
IBIlya Y. Barkov
Ilya Y. Barkov
OSOlga K. Stupko
Olga K. Stupko
MKMaria V. Kuznetsova
Maria V. Kuznetsova
AGAndrey Y. Goltsov
Andrey Y. Goltsov
GSGennady T. Sukhikh
Gennady T. Sukhikh
Background: PWS is challenging to diagnose prenatally due to a lack of precise and well‐characterized fetal phenotypes and noninvasive markers. Here we present the case of prenatal diagnosis of Prader‐Willi syndrome, which was suspected with whole‐genome NIPS.Methods: Whole‐genome noninvasive prenatal screening showed a high risk for trisomy 15. Amniocentesis followed by FISH analysis and SNP‐based chromosomal microarray was performed.Results: Simultaneous analysis of maternal and fetal samples with SNP microarrays demonstrated maternal uniparental disomy (UPD).Conclusion: The presented case is the first case of PWS described in detail, which was suspected by NIPS results. It demonstrates that the choice of confirmation methods concerning the time needed is crucial for the right diagnosis. We suppose that prenatal testing of UPD is essential for chromosome regions, which play a key role in the appearance of various gene‐imprinting failure syndromes like PWS or AS.

29 December 2017 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
JSJekaterina Shubina
Jekaterina Shubina
DTDmitry Yu Trofimov
Dmitry Yu Trofimov
IBIlya Yu Barkov
Ilya Yu Barkov
OSOlga K. Stupko
Olga K. Stupko
AGAndrey Yu Goltsov
Andrey Yu Goltsov
GSGennady T. Sukhikh
Gennady T. Sukhikh

20 July 2024 in Human Genetics and Genomics Advances
Verified
Journal Article
Open access
JSJekaterina Shubina
Jekaterina Shubina
ETEkaterina Tolmacheva
Ekaterina Tolmacheva
DMDmitry Maslennikov
Dmitry Maslennikov
TKTaisiya Kochetkova
Taisiya Kochetkova
IMIrina Mukosey
Irina Mukosey
GSGennady Sukhih
Gennady Sukhih
The effective implementation of whole-exome sequencing- and whole-genome sequencing-based diagnostics in the management of children affected with genetic diseases and the rapid decrease in the cost of next-generation sequencing (NGS) enables the expansion of this method to newborn genetic screening programs. Such NGS-based screening greatly increases the number of diseases that can be detected compared to conventional newborn screening, as the latter is aimed at early detection of a limited number of inborn diseases. Moreover, genetic testing provides new possibilities for family members of the proband, as many variants responsible for adult-onset conditions are inherited from the parents. However, the idea of NGS-based screening in healthy children raises issues of medical and ethical integrity as well as technical questions, including interpretation of the observed variants. Pilot studies have shown that both parents and medical professionals have moved forward and are enthused about these new possibilities. However, either the number of participants or the number of genes studied in previous investigations thus far has been limited to a few hundred, restricting the scope of potential findings. Our current study (NCT05325749) includes 7,000 apparently healthy infants born at our center between February 2021 and May 2023, who were screened for pathogenic variants in 2,350 genes. Clinically significant variants associated with early-onset diseases that can be treated, prevented, or where symptoms can be alleviated with timely introduced symptomatic therapy, were observed in 0.9% of phenotypically normal infants, 2.1% of the screened newborns were found to carry variants associated with reduced penetrance or monogenic diseases of adult-onset and/or variable expressivity, and 0.3% had chromosomal abnormalities. Here, we report our results and address questions regarding the interpretation of variants in newborns who were presumed to be healthy.

11 February 2025 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
PTPolina Tsabai
Polina Tsabai
NPNadezhda S. Pavlova
Nadezhda S. Pavlova
TSTaras Shatylko
Taras Shatylko
ZKZaira Kh. Kumykova
Zaira Kh. Kumykova
OSOlga K. Stupko
Olga K. Stupko
DTDmitry Yu. Trofimov
Dmitry Yu. Trofimov

14 May 2024 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
ETEkaterina Tolmacheva
Ekaterina Tolmacheva
ABAnna S. Bolshakova
Anna S. Bolshakova
JSJekaterina Shubina
Jekaterina Shubina
MRMargarita S. Rogacheva
Margarita S. Rogacheva
AEAlexey N. Ekimov
Alexey N. Ekimov
GSGennady T. Sukhikh
Gennady T. Sukhikh
Background: Whole exome sequencing allows rapid identification of causative single nucleotide variants and short insertions/deletions in children with congenital anomalies and/or intellectual disability, which aids in accurate diagnosis, prognosis, appropriate therapeutic interventions, and family counselling. Recently, de novo variants in the MED13 gene were described in patients with an intellectual developmental disorder that included global developmental delay, mild congenital heart anomalies, and hearing and vision problems in some patients. Results: Here we describe an infant who carried a de novo p.Pro835Ser missense variant in the MED13 gene, according to whole exome trio sequencing. He presented with congenital heart anomalies, dysmorphic features, hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more severe condition compared to previously described patients. Conclusions: Therefore, we propose to expand the MED13-associated phenotype to include severe complications that could end up with multiple organ failure and neonatal death.